{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:29:40Z","timestamp":1785796180831,"version":"3.56.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005343","name":"IMSS AC Foundation","doi-asserted-by":"publisher","award":["R-2025-785-010"],"award-info":[{"award-number":["R-2025-785-010"]}],"id":[{"id":"10.13039\/501100005343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.yebeh.2025.110675","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T21:14:28Z","timestamp":1756502068000},"page":"110675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune-mediated inflammatory conditions in epilepsy: role of autoimmunity"],"prefix":"10.1016","volume":"172","author":[{"given":"Araceli","family":"Reyes-Cuayahuitl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Araceli","family":"Estrada-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeli","family":"Orea-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Vega-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Li","family":"Chew-Irra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefany Ramos","family":"\u2013L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5289-8500","authenticated-orcid":false,"given":"Sandra","family":"Orozco-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9971","key":"10.1016\/j.yebeh.2025.110675_b0005","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"issue":"10172","key":"10.1016\/j.yebeh.2025.110675_b0010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110675_b0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.yebeh.2025.110675_b0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2012.04.004","article-title":"The role of inflammation in epileptogenesis","volume":"69","author":"Vezzani","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2025.110675_b0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0165-5728(02)00261-8","article-title":"Antibodies against GluR3 peptides are not specific for rasmussen\u2019s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures","volume":"131","author":"Mantegazza","year":"2002","journal-title":"J Neuroimmunol"},{"issue":"5172","key":"10.1016\/j.yebeh.2025.110675_b0030","doi-asserted-by":"crossref","DOI":"10.1126\/science.8036512","article-title":"Autoantibodies to glutamate receptor GluR3 in Rasmussen\u2019s encephalitis","volume":"265","author":"Rogers","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.yebeh.2025.110675_b0035","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ni0602-500","article-title":"Autoimmune epilepsy","volume":"3","author":"Levite","year":"2002","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0040","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110675_b0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13311-019-00750-3","article-title":"Autoimmune epilepsy","volume":"16","author":"Husari","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110675_b0050","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/epi.16571","article-title":"Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions","volume":"61","author":"Steriade","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1474-4422(13)70260-6","article-title":"Rasmussen\u2019s encephalitis: clinical features, pathobiology, and treatment advances","volume":"13","author":"Varadkar","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.seizure.2020.02.018","article-title":"Could the 2017 ILAE and the four-dimensional epilepsy classifications be merged to a new \u201cIntegrated Epilepsy Classification\u201d?","volume":"78","author":"Rosenow","year":"2020","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110675_b0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41582-025-01089-4","article-title":"Autoimmune encephalitis-associated epilepsy","volume":"21","author":"Steriade","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"18","key":"10.1016\/j.yebeh.2025.110675_b0075","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","article-title":"Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy","volume":"82","author":"Toledano","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110675_b0080","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jamaneurol.2021.3113","article-title":"Discerning the role of autoimmunity and autoantibodies in epilepsy: a review","volume":"78","author":"Steriade","year":"2021","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological autoantibody prevalence in epilepsy of unknown etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110675_b0090","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/epi.14534","article-title":"Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies","volume":"59","author":"N\u00f3brega-Jr","year":"2018","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110675_b0095","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/epi.13834","article-title":"Prevalence and outcome of late-onset seizures due to autoimmune etiology: a prospective observational population-based cohort study","volume":"58","author":"von Podewils","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0100","doi-asserted-by":"crossref","unstructured":"de Bruijn M, Bastiaansen AEM, Mojzisova H, van Son- deren A, Thijs RD, Majoie MJM, et al. Antibodies contributing to focal epilepsy signs and symptoms score. Ann Neurol. 2021; 89(4):698\u2013710. doi: 10.1002\/ana.26013.","DOI":"10.1002\/ana.26013"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13317-019-0124-6","article-title":"Associations between HLA and autoimmune neurological diseases with autoantibodies","volume":"11","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.yebeh.2025.110675_b0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.24860","article-title":"Anti-LGI1 encephalitis is associated with unique HLA subtypes","volume":"81","author":"Kim","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0115","doi-asserted-by":"crossref","unstructured":"Dandekar S, Wijesuriya H, Geiger T, Hamm D, Mathern GW, Owens GC. Shared HLA, Class I, Alleles II. Clonally restricted public and private brain-infiltrating \u03b1\u03b2 T cells in a cohort of Rasmussen encephalitis surgery patients. Frontiers in Immunology. 2016; 7:608. doi: 10.3389\/immu.2016.00608. eCollection 2016.","DOI":"10.3389\/fimmu.2016.00608"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110675_b0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.autrev.2009.12.012","article-title":"Autoimmune diseases: solution of the environmental, immunological, and genetic components with principles for immunotherapy and transplantation","volume":"9","author":"Adams","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.yebeh.2025.110675_b0125","doi-asserted-by":"crossref","unstructured":"Milatovic D, Zaja-Milatovic S, Breyer RM, Aschner M, Montine TJ. Chapter 56. Neuroinflammation and Oxidative Injury in Developmental Neurotoxicity. In: Reproductive and Developmental Toxicology (Third Edition): Academic Press; 2017.1129-1140. doi.org\/10.1016\/B978-0-323-89773-0.00056-4.","DOI":"10.1016\/B978-0-323-89773-0.00056-4"},{"key":"10.1016\/j.yebeh.2025.110675_b0130","doi-asserted-by":"crossref","unstructured":"Riazi K, Galic MA, Pittman QJ. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability Epilepsy Res. 2010; 89:34-42. Doi: 10.1016\/j.eplepsyres.2009.09.004.","DOI":"10.1016\/j.eplepsyres.2009.09.004"},{"key":"10.1016\/j.yebeh.2025.110675_b0135","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/j.1528-1167.2005.00298.x","article-title":"Brain inflammation in epilepsy: experimental and clinical evidence","volume":"46","author":"Vezzani","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2015.02.029","article-title":"Albumin induces excitatory synaptogenesis through astrocytic TGF-\u03b2\/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction","volume":"78","author":"Weissberg","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.yebeh.2025.110675_b0150","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.55.12.1823","article-title":"Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy","volume":"55","author":"Bien","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110675_b0155","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1212\/01.wnl.0000276946.08412.ef","article-title":"Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy","volume":"69","author":"Bien","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110675_b0160","doi-asserted-by":"crossref","unstructured":"Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability Neuropharmacology. 2015; 96:70-82. doi: 10.1016\/j.neuropharm.2014.10.027.","DOI":"10.1016\/j.neuropharm.2014.10.027"},{"key":"10.1016\/j.yebeh.2025.110675_b0165","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1523\/JNEUROSCI.6210-10.2011","article-title":"Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy","volume":"31","author":"Zattoni","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2025.110675_b0170","doi-asserted-by":"crossref","unstructured":"Jarrott B, and Aprico K. Microglia: protective and pathogenic mediators. Inflammatory diseases of the central nervous system. Cambridge University Press, Cambridge. 2010: 15-26.","DOI":"10.1017\/CBO9781139195805.003"},{"key":"10.1016\/j.yebeh.2025.110675_b0175","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.seizure.2021.07.028","article-title":"Temporal lobe epilepsy: evaluation of central and systemic immune-inflammatory features associated with drug resistance","volume":"91","author":"Toledo","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110675_b0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.seizure.2020.07.023","article-title":"Rasmussen\u2019s encephalitis: from immune pathogenesis towards targeted-therapy","volume":"81","author":"Orsini","year":"2020","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110675_b0185","first-page":"513","article-title":"Antibody-mediated erythrolysis and erythrophagocytosis by human monocytes, macrophages and activated macrophages. Evidence for distinction between involvement of high-affinity and low-affinity receptors for IgG by using different erythroid target cells","volume":"63","author":"R\u00fcegg","year":"1988","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2006.03.005","article-title":"B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target","volume":"112","author":"Dalakas","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110675_b0195","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune central nervous system diseases","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.yebeh.2025.110675_b0200","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00415-012-6657-5","article-title":"Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system","volume":"260","author":"Melzer","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0205","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-022-02448-x","article-title":"Complement activation contributes to GAD antibody-associated encephalitis","volume":"144","author":"Chuquisana","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.yebeh.2025.110675_b0210","doi-asserted-by":"crossref","unstructured":"Troscher AR, Mair KM, Verd\u00fa de Juan L et al (2022) Temporal lobe epilepsy with GAD antibodies: neurons killed by T cells not by complement membrane attack complex. Brain. https:\/\/doi.org\/10.1093\/brain\/awac404.","DOI":"10.1093\/brain\/awac404"},{"key":"10.1016\/j.yebeh.2025.110675_b0215","doi-asserted-by":"crossref","DOI":"10.1007\/s00115-024-01695-5","article-title":"(Auto\u2013)Immunit\u00e4t bei fokaler Epilepsie: Mechanismen (auto\u2013)immun-inflammatorischer epileptogener Neurodegeneration","volume":"95","author":"Melzer","year":"2024","journal-title":"Nervenarzt"},{"key":"10.1016\/j.yebeh.2025.110675_b0220","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.neuron.2012.07.009","article-title":"Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability","volume":"75","author":"Ince-Dunn","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.yebeh.2025.110675_b0225","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0230","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acn3.444","article-title":"NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody","volume":"4","author":"Malviya","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0235","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ana.25699","article-title":"N-methyl-D-aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function","volume":"87","author":"Matute","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0240","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1916337118","article-title":"Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis","author":"Brandle","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.yebeh.2025.110675_b0245","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1212\/NXI.0000000000000232","article-title":"Evidence of a pathogenic role for CD8(+) T cells in anti-GABAB receptor limbic encephalitis","volume":"3","author":"Golombeck","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.yebeh.2025.110675_b0250","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0255","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0260","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.22297","article-title":"Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia","volume":"69","author":"Lancaster","year":"2011","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110675_b0265","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.mayocp.2021.02.019","article-title":"Autoimmune encephalitis-related seizures and epilepsy: diagnostic and therapeutic approaches","volume":"96","author":"Chen","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110675_b0270","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume":"30","author":"Spatola","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.seizure.2018.06.021","article-title":"Electroclinical features of seizures associated with autoimmune encephalitis","volume":"60","author":"Steriade","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110675_b0280","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jns.2018.10.026","article-title":"Factors underlying the development of chronic temporal lobe epilepsy in autoimmune encephalitis","volume":"396","author":"Casciato","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2025.110675_b0285","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0290","doi-asserted-by":"crossref","unstructured":"Bordonne M, Chawki MB, Doyen M et al. Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging 2021;48:3847\u20133858. https:\/\/doi.org\/10.1007\/s00259- 021-05299-y.","DOI":"10.1007\/s00259-021-05299-y"},{"key":"10.1016\/j.yebeh.2025.110675_b0295","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1212\/NXI.0000000000000663","article-title":"Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient","volume":"17","author":"Cellucci","year":"2020","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110675_b0300","first-page":"276","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"LancetNeurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0305","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329195","article-title":"Immune Epilepsies Study Group of the Italian League against Epilepsy. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy","author":"Matricardi","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0310","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s13760-017-0796-5","article-title":"Investigation of anti-neuronal antibodies in status epilepticus of unknown etiology: a prospective study","volume":"117","author":"Atmaca","year":"2017","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110675_b0315","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1007\/s00415-024-12385-2","article-title":"Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study","volume":"271","author":"Fonte","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0320","article-title":"Successfully treated anti-GAD limbic encephalitis in a 15-year-old diabetic boy with intravenous immunoglobulin: case report","volume":"5","author":"Fattahzadeh Ardalani","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.yebeh.2025.110675_b0325","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1212\/WNL.57.8.1511","article-title":"GluR3 Antibodies: prevalence in focal epilepsy but no specificity for rasmussen's encephalitis","volume":"57","author":"Wiendl","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110675_b0330","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0165-5728(02)00261-8","article-title":"Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures","volume":"131","author":"Mantegazza","year":"2002","journal-title":"J Neuroimmunol"},{"issue":"12","key":"10.1016\/j.yebeh.2025.110675_b0335","article-title":"Autoimmune epilepsy - novel multidisciplinary analysis, discoveries and insights","volume":"12","author":"Levite","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.yebeh.2025.110675_b0340","doi-asserted-by":"crossref","unstructured":"Levite M. Glutamate Receptor Antibodies in Neurological Diseases: Anti-AMPA-GluR3 Antibodies, Anti-NMDA-NR1 Antibodies, Anti-NMDANR2A\/B Antibodies, Anti-mGluR1 Antibodies or Anti-mGluR5 Antibodies Are Present in Subpopulations of Patients With Either: Epilepsy, Encephalitis, Cerebellar Ataxia, Systemic Lupus Erythematosus (SLE) and Neuropsychiatric SLE, Sjogren's Syndrome, Schizophrenia, Mania or Stroke.These Autoimmune Anti-Glutamate Receptor Antibodies Can Bind Neurons in Few Brain Regions, Activate Glutamate Receptors, Decrease Glutamate Receptor's Expression, Impair Glutamate-Induced Signaling and Function, Activate Blood Brain Barrier Endothelial Cells, Kill Neurons, Damage the Brain, Induce Behavioral\/Psychiatric\/Cognitive Abnormalities and Ataxia in Animal Models, and Can be Removed or Silenced in Some Patients by Immunotherapy. 2014. J Neural Transm; 121:1029\u201375.","DOI":"10.1007\/s00702-014-1193-3"},{"key":"10.1016\/j.yebeh.2025.110675_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.838389","article-title":"GluR3B antibody was a biomarker for drug-resistant epilepsy in patients with focal to bilateral tonic-clonic seizures","volume":"13","author":"Lai","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.yebeh.2025.110675_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102462","article-title":"Dual-targeted autoimmune sword in fatal epilepsy: Patient's glutamate receptor AMPA GluR3B peptide autoimmune antibodies bind, induce Reactive Oxygen Species (ROS) in, and kill both human neural cells and T cells","volume":"112","author":"Levite","year":"2020","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110675_b0355","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.1528-1167.2012.03565.x","article-title":"Evolution of the EEG in children with Rasmussen's syndrome","volume":"53","author":"Longaretti","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0360","doi-asserted-by":"crossref","unstructured":"Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1 linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci USA. 2010;107:3799\u20133804. https:\/\/doi.org\/10.1073\/pnas.0914537107.","DOI":"10.1073\/pnas.0914537107"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110675_b0365","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/brain\/awq171","article-title":"Electroclinical characterization of epileptic seizures in leucine-rich, glioma inactivated1-deficient mice","volume":"133","author":"Chabrol","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110675_b0370","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/brain\/awaa104","article-title":"Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms","volume":"143","author":"Ramberger","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2025.110675_b0375","doi-asserted-by":"crossref","DOI":"10.1111\/epi.13784","article-title":"Innate and adaptive immunity in human epilepsies","volume":"58","author":"Bauer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0380","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/ene.13324","article-title":"Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies\u2014a national cohort study","volume":"24","author":"Celicanin","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0385","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","article-title":"Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies","volume":"74","author":"Finke","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0390","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1007\/s00415-022-11162-3","article-title":"Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies","volume":"269","author":"Guery","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0395","doi-asserted-by":"crossref","unstructured":"Kornau HC, Kreye J, Stumpf A, Fukata Y, Parthier D, Sam- mons RP, et al. Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann Neurol. 2020;87(3):405\u201318. doi: 10.1002\/ana.25666.","DOI":"10.1002\/ana.25666"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110675_b0400","first-page":"3144","article-title":"LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity, and memory","volume":"141","author":"Petit-Pedrol","year":"2018","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110675_b0405","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-022-01826-9","article-title":"Immune mechanisms in epileptogenesis: update on diagnosis and treatment of autoimmune epilepsy syndromes","volume":"83","author":"Flammer","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2025.110675_b0410","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00415-014-7408-6","article-title":"Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity","volume":"261","author":"Malter","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0415","doi-asserted-by":"crossref","unstructured":"Uribe-San-Mart\u00edn R, Ciampi E, Santiba\u00f1ez R, Irani SR, M\u00e1rquez A, Cruz JP, Soler B, Miranda MC, Henr\u00edquez M, C\u00e1rcamo C. LGI1-antibody associated epilepsy successfully treated in the outpatient setting. J Neuroimmunol. 2020; 15 (345): 577268. doi: 10.1016\/j.jneuroim.2020.577268. Epub 2020 May 23. PMID: 32480242; PMCID: PMC7339132.","DOI":"10.1016\/j.jneuroim.2020.577268"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110675_b0420","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1007\/s00415-024-12594-9","article-title":"LGI1 encephalitis: potentially complement-activating anti-LGI1-IgG subclasses 1\/2\/3 are associated with the development of hippocampal sclerosis","volume":"271","author":"Bien","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0425","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1111\/epi.17338","article-title":"Seizure underreporting in LGI1 and CASPR2 antibody encephalitis","volume":"63","author":"Baumgartner","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120540","article-title":"Glutamic acid decarboxylase antibody-associated neurological syndromes: clinical and antibody characteristics and therapy response","volume":"445","author":"Madlener","year":"2023","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2025.110675_b0435","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.990553","article-title":"Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: clinical spectrum and prognosis of a cohort from China","volume":"13","author":"Bai","year":"2022","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110675_b0440","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.seizure.2014.04.009","article-title":"Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications","volume":"23","author":"Lilleker","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110675_b0445","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0450","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.21917","article-title":"Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis","volume":"67","author":"Malter","year":"2010","journal-title":"Ann Neurol"},{"issue":"341","key":"10.1016\/j.yebeh.2025.110675_b0455","article-title":"Immune-mediated epilepsy with GAD65 antibodies","volume":"15","author":"Li","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110675_b0460","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3389\/fimmu.2018.02708","article-title":"Management of autoimmune encephalitis: an observational monocentric study of 38 patients","volume":"22","author":"Macher","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110675_b0465","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1684\/epd.2019.1094","article-title":"GAD65-Ab encephalitis and subtle focal status epilepticus","volume":"21","author":"Goudot","year":"2019","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2025.110675_b0470","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110675_b0475","first-page":"81","article-title":"Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients","volume":"22","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110675_b0480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2016.02.006","article-title":"Refractory status epilepticus and autoimmune encephalitis with GABAAR and GAD65 antibodies: a case report","volume":"37","author":"Gagnon","year":"2016","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110675_b0485","article-title":"Continuous visual focal status epilepticus as the primary presentation of NMDA-R and GAD65-R autoimmune epilepsy","volume":"26","author":"Paredes-Arag\u00f3n","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0490","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1211812","article-title":"High frequency of cerebrospinal fluid autoantibodies in patients with seizures or epilepsies of unknown etiology","volume":"14","author":"Schulz","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-023-03514-x","article-title":"Clinical characteristics of autoimmune encephalitis with co-existence of multiple anti-neuronal antibodies","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110675_b0500","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.16788","article-title":"Inflammation, ictogenesis, and epileptogenesis: an exploration through human disease","volume":"62","author":"Tan","year":"2021","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110675_b0505","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"Faciobrachial dystonic seizures study group. The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0510","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2025.110675_b0515","article-title":"Do all children with autoimmune encephalitis need aggressive immunotherapy?","volume":"15","author":"Kamate","year":"2020","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.yebeh.2025.110675_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756285617722347","article-title":"Treatment strategies for autoimmune encephalitis","volume":"11","author":"Shin","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0525","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/ane.12575","article-title":"Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy","volume":"135","author":"Von Rhein","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0530","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7861\/clinmed.2020-0241","article-title":"Update on the diagnosis and management of autoimmune encephalitis","volume":"20","author":"Ellul","year":"2020","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0535","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1212\/WNL.46.1.242","article-title":"Plasmapheresis in Rasmussen's encephalitis","volume":"46","author":"Andrews","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110675_b0540","doi-asserted-by":"crossref","unstructured":"Cantar\u00edn-Extremera V, Jim\u00e9nez-Legido M, Sebasti\u00e1n-P\u00e9rez E, Duat-Rodr\u00edguez A, Ruiz-Falc\u00f3 Rojas ML. Inmunoadsorci\u00f3n y plasmaf\u00e9resis: \u00bfposibilidades de tratamiento en la encefalitis de Rasmussen? [Immunoadsorption and plasmapheresis: possible treatments for Rasmussen's encephalitis?]. Rev Neurol. 2020 Feb 16;70(4):159-160. Spanish. doi: 10.33588\/rn.7004.2019439.","DOI":"10.33588\/rn.7004.2019439"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0545","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.51.1.302","article-title":"Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis","volume":"51","author":"Antozzi","year":"1998","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.yebeh.2025.110675_b0550","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1212\/01.WNL.0000099074.04539.E0","article-title":"Experience with immunomodulatory treatments in Rasmussen's encephalitis","volume":"61","author":"Granata","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146455","article-title":"Effect of immunotherapy on seizure outcome in patients with autoimmune encephalitis: a prospective observational registry study","volume":"11","author":"Byun","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110675_b0560","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2025.110675_b0565","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10072-013-1327-7","article-title":"A complex case of anti-GAD antibody-related syndrome treated with Rituximab","volume":"34","author":"Baroncini","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2025.110675_b0570","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1684\/epd.2016.0797","article-title":"Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes","volume":"18","author":"Khawaja","year":"2016","journal-title":"Epileptic Disord"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2025.110675_b0575","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/epi.12184","article-title":"Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management","volume":"54","author":"Bien","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110675_b0580","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.seizure.2015.04.007","article-title":"Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy","volume":"29","author":"Dubey","year":"2015","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110675_b0585","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1212\/CON.0000000000000715","article-title":"Update on antiepileptic drugs 2019","volume":"25","author":"Abou-Khalil","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110675_b0590","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1212\/NXI.0000000000000353","article-title":"Antiepileptic drug therapy in patients with autoimmune epilepsy","volume":"4","author":"Feyissa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.yebeh.2025.110675_b0595","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2018.05.004","article-title":"Efficacy of antiepileptic drugs in autoimmune epilepsy: a systematic review","volume":"59","author":"Cabezudo-Garc\u00eda","year":"2018","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110675_b0600","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200151","article-title":"Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies","volume":"10","author":"Serrano-Castro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110675_b0605","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2025.110675_b0610","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2015.05.017","article-title":"Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies","volume":"30","author":"Malter","year":"2015","journal-title":"Seizure"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2025.110675_b0615","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/epi.13785","article-title":"Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy","volume":"58","author":"Barker-Haliski","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3349\/ymj.2008.49.1.1","article-title":"Role of brain inflammation in epileptogenesis","volume":"49","author":"Choi","year":"2008","journal-title":"Yonsei Med J"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110675_b0625","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/nan.12444","article-title":"Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies","volume":"44","author":"van Vliet","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110675_b0630","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jnc.12784","article-title":"The antiseizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1 beta and TNF-alpha expression in rat hippocampus","volume":"130","author":"Gomez","year":"2014","journal-title":"J Neurochem"},{"key":"10.1016\/j.yebeh.2025.110675_b0635","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/806162","article-title":"Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro","volume":"2014","author":"Himmerich","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.yebeh.2025.110675_b0640","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/135502801753170345","article-title":"Diazepam inhibits HIV-1 tat-induced migration of human microglia","volume":"7","author":"Lokensgard","year":"2001","journal-title":"J Neurovirol"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110675_b0645","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1535759720928269","article-title":"Treatment of refractory convulsive status epilepticus: a comprehensive review by the American epilepsy society treatments committee","volume":"20","author":"Vossler","year":"2020","journal-title":"Epilepsy Curr"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025004159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025004159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:31:40Z","timestamp":1780299100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025004159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":129,"alternative-id":["S1525505025004159"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110675","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated inflammatory conditions in epilepsy: role of autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110675"}}